Sandra Tingsgård
Research Subjects
Sandra Tingsgård has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Simone Bastrup Israelsen
Department of Infectious Diseases, Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark
4 shared publications Thomas Benfield
Center of Research & Disruption of Infectious Diseases, Department of Infectious Diseases, Copenhagen University Hospital–Amager and Hvidovre, Hvidovre, Denmark
3 shared publicationsAndreas Knudsen
Department of Respiratory Medicine and Infectious Diseases, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark
2 shared publicationsBirgitte Lindegaard
Department of Respiratory Medicine and Infectious Diseases, Copenhagen University Hospital, North Zealand, Hillerød, Denmark
2 shared publicationsChristian Østergaard
Department of Clinical Microbiology, Copenhagen University Hospital–Amager and Hvidovre, Hvidovre, Denmark
2 shared publicationsIsik S Johansen
Department of Infectious Diseases, Odense University Hospital, Odense, Denmark
2 shared publications
Latest Publications
- Open Access
- 2 January 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (1) , e2352314
Early Switch From Intravenous to Oral Antibiotics for Patients With Uncomplicated Gram-Negative Bacteremia
The rising global incidence of gram-negative bacteremia contributes to significant morbidity, mortality, and challenges in clinical management.1,2 The optimal treatment duration for gram-negative bacteremia has received increased attention in recent years. While randomized clinical trials (RCTs) have explored this topic, there is a lack of emphasis on the appropriate timing for transitioning from intravenous (IV) to oral antibiotic therapy. Early transition could lead to reduced hospital stays, lower health care costs, and improved patient quality of life.3-7 Additionally, switching to oral therapy may help mitigate the risks associated with IV catheters while also facilitating an earlier return to regular activities of daily living.3,7
- 2 January 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (1) , e2352314
Open AccessEarly Switch From Intravenous to Oral Antibiotics for Patients With Uncomplicated Gram-Negative Bacteremia
The rising global incidence of gram-negative bacteremia contributes to significant morbidity, mortality, and challenges in clinical management.1,2 The optimal treatment duration for gram-negative bacteremia has received increased attention in recent years. While randomized clinical trials (RCTs) have explored this topic, there is a lack of emphasis on the appropriate timing for transitioning from intravenous (IV) to oral antibiotic therapy. Early transition could lead to reduced hospital stays, lower health care costs, and improved patient quality of life.3-7 Additionally, switching to oral therapy may help mitigate the risks associated with IV catheters while also facilitating an earlier return to regular activities of daily living.3,7
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
241. Early switch from intravenous to oral antibiotics in patients with Gram-negative bacteremia – a target trial emulation
Gram-negative bacteremia is a global health concern, that continues to cause significant morbidity and mortality. Intravenous (IV) antibiotics are typically the first-line treatment; however, it is unclear when it is appropriate to switch to oral antibiotics in order to maintain positive outcomes. An early switch from intravenous to oral antibiotics may have several advantages, including reduced hospital stay, lower healthcare costs, and improved patient quality of life. This study investigates the effectiveness of early switch to oral antibiotics in patients with Gram-negative bacteremia using a target trial framework. We outlined the protocol for a target trial to estimate the effect of 1) switching to oral antibiotics within four days after initial blood culture compared with 2) continuing IV antibiotic treatment throughout the treatment course on 90-day all-cause mortality. We then emulated the trial using a cohort of adult patients with Gram-negative bacteremia from 2018 through 2022 admitted to four hospitals in the Capital Region of Denmark. Patients who were immunosuppressed, transitioned to hospice care, had polymicrobial infection, were not clinically stable within four days of blood culture, or did not receive adequate empirical antibiotic treatment were excluded. Inverse probability of treatment weighting was applied to adjust for confounding. Intention-to-treat analysis was performed using pooled logistic regression to estimate absolute risk, risk difference, and risk ratio. 95% confidence intervals (CI) were computed using bootstrapping. Our findings indicate that an early switch to oral antibiotic treatment within four days may be a safe and effective alternative to continued IV treatment in patients hospitalised with uncomplicated Gram-negative bacteremia. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access241. Early switch from intravenous to oral antibiotics in patients with Gram-negative bacteremia – a target trial emulation
Gram-negative bacteremia is a global health concern, that continues to cause significant morbidity and mortality. Intravenous (IV) antibiotics are typically the first-line treatment; however, it is unclear when it is appropriate to switch to oral antibiotics in order to maintain positive outcomes. An early switch from intravenous to oral antibiotics may have several advantages, including reduced hospital stay, lower healthcare costs, and improved patient quality of life. This study investigates the effectiveness of early switch to oral antibiotics in patients with Gram-negative bacteremia using a target trial framework. We outlined the protocol for a target trial to estimate the effect of 1) switching to oral antibiotics within four days after initial blood culture compared with 2) continuing IV antibiotic treatment throughout the treatment course on 90-day all-cause mortality. We then emulated the trial using a cohort of adult patients with Gram-negative bacteremia from 2018 through 2022 admitted to four hospitals in the Capital Region of Denmark. Patients who were immunosuppressed, transitioned to hospice care, had polymicrobial infection, were not clinically stable within four days of blood culture, or did not receive adequate empirical antibiotic treatment were excluded. Inverse probability of treatment weighting was applied to adjust for confounding. Intention-to-treat analysis was performed using pooled logistic regression to estimate absolute risk, risk difference, and risk ratio. 95% confidence intervals (CI) were computed using bootstrapping. Our findings indicate that an early switch to oral antibiotic treatment within four days may be a safe and effective alternative to continued IV treatment in patients hospitalised with uncomplicated Gram-negative bacteremia. All Authors: No reported disclosures
- 9 November 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (2) , 292-300
Emulating a Target Trial of Shorter Compared to Longer Course of Antibiotic Therapy for Gram-Negative Bacteremia
Despite the availability of antimicrobial therapies, Gram-negative bacteremia remains a significant cause of morbidity and mortality on a global level. Recent randomized controlled trials support shorter antibiotic treatment duration for individuals with uncomplicated Gram-negative bacteremia. The target trial framework using the cloning approach utilizes real-world data but eliminates the issue of immortal time bias seen in observational studies by emulating the analysis of randomized trials with full adherence. A hypothetical target trial allocating individuals with Gram-negative bacteremia to either short antibiotic treatment duration (5-7 days) or longer antibiotic treatment duration (8-14 days) was specified and emulated using the cloning, censoring, and weighting approach. The primary outcome was 90-day all-cause mortality. Secondary outcome was a composite endpoint of clinical and microbiological relapse. The emulated trial included individuals from four hospitals in Copenhagen from 2018 through 2021. 1040 individuals were included. The median age of the cohort was 76 years, the majority were male (54%), had community-acquired Gram-negative bacteremia (86%), urinary tract infection as the source of the infection (78%), and Escherichia coli as the pathogen of the infection (73%). The adjusted 90-day risk difference in all-cause mortality was 1.3 (95% CI -0.7, 3.3), and the risk ratio was 1.12 (95% CI 0.89, 1.37). The adjusted 90-day risk difference in relapse was 0.7 (95% CI -2.3, 3.8), and the risk ratio was 1.07 (95% CI 0.71, 1.45). We found comparative outcomes for shorter treatment duration compared to longer treatment duration in patients with Gram-negative bacteremia.
- 9 November 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (2) , 292-300
Emulating a Target Trial of Shorter Compared to Longer Course of Antibiotic Therapy for Gram-Negative Bacteremia
Despite the availability of antimicrobial therapies, Gram-negative bacteremia remains a significant cause of morbidity and mortality on a global level. Recent randomized controlled trials support shorter antibiotic treatment duration for individuals with uncomplicated Gram-negative bacteremia. The target trial framework using the cloning approach utilizes real-world data but eliminates the issue of immortal time bias seen in observational studies by emulating the analysis of randomized trials with full adherence. A hypothetical target trial allocating individuals with Gram-negative bacteremia to either short antibiotic treatment duration (5-7 days) or longer antibiotic treatment duration (8-14 days) was specified and emulated using the cloning, censoring, and weighting approach. The primary outcome was 90-day all-cause mortality. Secondary outcome was a composite endpoint of clinical and microbiological relapse. The emulated trial included individuals from four hospitals in Copenhagen from 2018 through 2021. 1040 individuals were included. The median age of the cohort was 76 years, the majority were male (54%), had community-acquired Gram-negative bacteremia (86%), urinary tract infection as the source of the infection (78%), and Escherichia coli as the pathogen of the infection (73%). The adjusted 90-day risk difference in all-cause mortality was 1.3 (95% CI -0.7, 3.3), and the risk ratio was 1.12 (95% CI 0.89, 1.37). The adjusted 90-day risk difference in relapse was 0.7 (95% CI -2.3, 3.8), and the risk ratio was 1.07 (95% CI 0.71, 1.45). We found comparative outcomes for shorter treatment duration compared to longer treatment duration in patients with Gram-negative bacteremia.
- Open Access
Short-course antibiotic therapy of 5 days in community-acquired pneumonia (CAP5): study protocol for a randomised controlled trial
Introduction The optimal duration of antibiotic therapy for community-acquired pneumonia (CAP) is unsettled. Short-course therapy has proved successful in clinical trials but is not yet implemented in everyday clinical practice. Validation of results from randomised controlled trials is crucial to evaluate existing evidence and provide clinicians with assurance of using new treatment strategies. In a pragmatic framework, we aim to assess the use of short-course antibiotic therapy guided by the onset of clinical stability in patients hospitalised with CAP. Methods and analysis This study is a randomised controlled trial with a non-inferiority design that will examine the efficacy of short-course antibiotic therapy in patients hospitalised with CAP. From six hospitals across Denmark, we plan to enrol 564 patients between 2019 and 2024. Within 3–5 days after initiating antibiotic therapy, participants will be randomised 1:1 to parallel treatment arms: (1) short-course antibiotic therapy of 5 days or (2) antibiotic therapy of at least 7 days. The primary outcome will be 90-day readmission-free survival and will be estimated as an absolute risk difference with a predefined non-inferiority margin of −6%. Secondary outcomes will comprise other safety measures including new antibiotics, adverse events, length of hospital stay and postdischarge outpatient visits. Both intention-to-treat and per-protocol analyses will be performed. Ethics and dissemination This study has been approved by the Health Research Ethics Committee of the Capital Region of Denmark (identifier number: H-19014479). Trial data will be made available in anonymous form when the trial has ended. Trial registration number NCT04089787, ClinicalTrials.Gov.
Open AccessShort-course antibiotic therapy of 5 days in community-acquired pneumonia (CAP5): study protocol for a randomised controlled trial
Introduction The optimal duration of antibiotic therapy for community-acquired pneumonia (CAP) is unsettled. Short-course therapy has proved successful in clinical trials but is not yet implemented in everyday clinical practice. Validation of results from randomised controlled trials is crucial to evaluate existing evidence and provide clinicians with assurance of using new treatment strategies. In a pragmatic framework, we aim to assess the use of short-course antibiotic therapy guided by the onset of clinical stability in patients hospitalised with CAP. Methods and analysis This study is a randomised controlled trial with a non-inferiority design that will examine the efficacy of short-course antibiotic therapy in patients hospitalised with CAP. From six hospitals across Denmark, we plan to enrol 564 patients between 2019 and 2024. Within 3–5 days after initiating antibiotic therapy, participants will be randomised 1:1 to parallel treatment arms: (1) short-course antibiotic therapy of 5 days or (2) antibiotic therapy of at least 7 days. The primary outcome will be 90-day readmission-free survival and will be estimated as an absolute risk difference with a predefined non-inferiority margin of −6%. Secondary outcomes will comprise other safety measures including new antibiotics, adverse events, length of hospital stay and postdischarge outpatient visits. Both intention-to-treat and per-protocol analyses will be performed. Ethics and dissemination This study has been approved by the Health Research Ethics Committee of the Capital Region of Denmark (identifier number: H-19014479). Trial data will be made available in anonymous form when the trial has ended. Trial registration number NCT04089787, ClinicalTrials.Gov.
- Open Access
Short course antibiotic treatment of Gram-negative bacteraemia (GNB5): a study protocol for a randomised controlled trial
Introduction: Prolonged use of antibiotics is closely related to antibiotic-associated infections, antimicrobial resistance and adverse drug events. The optimal duration of antibiotic treatment for Gram-negative bacteremia (GNB) with a urinary tract source of infection is poorly defined. Methods and analysis: Investigator-initiated multicentre, non-blinded, non-inferiority randomised controlled trial with two parallel treatment arms. One arm will receive shortened antibiotic treatment of 5 days and the other arm will receive antibiotic treatment of 7 days or longer. Randomisation will occur in equal proportion (1:1) no later than day 5 of effective antibiotic treatment as determined by antibiogram. Immunosuppressed patients and those with GNB due to non-fermenting bacilli ( Acinetobacter spp, Pseudomonas spp), Brucella spp, Fusobacterium spp or polymicrobial growth are ineligible. The primary endpoint is 90-day survival without clinical or microbiological failure to treatment. Secondary endpoints include all-cause mortality, total duration of antibiotic treatment, hospital readmission and Clostridioides difficile infection. Interim safety analysis will be performed after the recruitment of every 100 patients. Given an event rate of 12%, a non-inferiority margin of 10%, and 90% power, the required sample size to determine non-inferiority is 380 patients. Analyses will be performed on both intention-to-treat and per-protocol populations. Ethics and dissemination: The study is approved by the Danish Regional Committee on Health Research (H-19085920) and the Danish Medicines Agency (2019-003282-17). The results of the main trial and each of the secondary endpoints will be submitted for publication in a peer-reviewed journal. Trial registration number: ClinicalTrials.Gov:NCT04291768 .
Open AccessShort course antibiotic treatment of Gram-negative bacteraemia (GNB5): a study protocol for a randomised controlled trial
Introduction: Prolonged use of antibiotics is closely related to antibiotic-associated infections, antimicrobial resistance and adverse drug events. The optimal duration of antibiotic treatment for Gram-negative bacteremia (GNB) with a urinary tract source of infection is poorly defined. Methods and analysis: Investigator-initiated multicentre, non-blinded, non-inferiority randomised controlled trial with two parallel treatment arms. One arm will receive shortened antibiotic treatment of 5 days and the other arm will receive antibiotic treatment of 7 days or longer. Randomisation will occur in equal proportion (1:1) no later than day 5 of effective antibiotic treatment as determined by antibiogram. Immunosuppressed patients and those with GNB due to non-fermenting bacilli ( Acinetobacter spp, Pseudomonas spp), Brucella spp, Fusobacterium spp or polymicrobial growth are ineligible. The primary endpoint is 90-day survival without clinical or microbiological failure to treatment. Secondary endpoints include all-cause mortality, total duration of antibiotic treatment, hospital readmission and Clostridioides difficile infection. Interim safety analysis will be performed after the recruitment of every 100 patients. Given an event rate of 12%, a non-inferiority margin of 10%, and 90% power, the required sample size to determine non-inferiority is 380 patients. Analyses will be performed on both intention-to-treat and per-protocol populations. Ethics and dissemination: The study is approved by the Danish Regional Committee on Health Research (H-19085920) and the Danish Medicines Agency (2019-003282-17). The results of the main trial and each of the secondary endpoints will be submitted for publication in a peer-reviewed journal. Trial registration number: ClinicalTrials.Gov:NCT04291768 .